Serevent, Foradil Use With Steroids Should Be Strongly Urged In Labeling
Executive Summary
Labeling for GSK's Serevent and Novartis/Schering's Foradil should include a stronger recommendation that the long-acting beta agonist bronchodilators be used concomitantly with inhaled corticosteroids, FDA's Pulmonary-Allergy Drugs Advisory Committee said
You may also be interested in...
AstraZeneca Shelves Symbicort Launch Until 2007 To Prolong Product Life
AstraZeneca is delaying the launch of its asthma therapy Symbicort (budesonide/formoterol) until mid-2007 as it works to develop a longer shelf life for the product, the company said
AstraZeneca Shelves Symbicort Launch Until 2007 To Prolong Product Life
AstraZeneca is delaying the launch of its asthma therapy Symbicort (budesonide/formoterol) until mid-2007 as it works to develop a longer shelf life for the product, the company said
No Breathing Room For Advair: GSK Combo Part Of Asthma Drug Restrictions
GlaxoSmithKline's asthma combination product Advair is included in an FDA advisory against first-line use of long-acting beta agonist bronchodilators despite an advisory committee review that suggested Advair was less risky than other products